SF Healthcare Week: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year
BiotechTV - News
00:00
Crohn's trial prospects and fibrosis signals
Marc expresses optimism for Crohn's results, noting effects on TH17 and potential anti-fibrotic activity to report later.
Play episode from 08:49
Transcript
